source
- Novartis faces another setback while Novo drops Nordisk partnershipThe latest edition of Endpoints Weekly notes that Novartis experienced another failure, though the newsletter does not provide details about the product or trial. It also reports that Novo Nordisk…
- Ultragenyx receives FDA approval for Fayuvi, first therapy for Sanfilippo syndrome type A, priced at $3.95 MThe FDA has approved Ultragenyx's gene therapy rebisufligene etisparvovec, to be sold under the brand name Fayuvi, for the treatment of Sanfilippo syndrome type A, an ultra-rare progressive neurolo…